



What we do

Anima Biotech is a drug discovery company with a novel technology that shows where, when and which proteins are being synthesized, in living cells, in real time. Our platform enables us to find drugs for some of the world's most severe diseases including targets that so far were considered "undruggable". Our drug discovery programs currently focus on neuro developmental diseases (Autism), Fibrosis and Viral Infections. Please watch the movie on our web site: www.animabiotech.com

Our Novel Approach

The search for new drugs centers on proteins. Proteins are the fundamental basis for the process of life, for understanding disease, and for developing new therapies. Many severe diseases are closely related to problems in protein production.

Most drugs act by chemically binding to the protein target, known to be related to the disease. Proteins have an amazing variety of shape, structure and function and are very complex. Once they are fully assembled, it is extremely difficult to understand and modify their behavior in the living cell. Our approach is dramatically different: instead of looking for drugs that bind to fully folded proteins, we discover drugs that inhibit the synthesis of the target protein by interfering with the protein translation machinery.

Our PSM technology and drug discovery platform

In each cell in our body, hundreds of thousands of ribosomes – protein production factories of the cell – are constantly producing proteins according to the cell's ever-changing needs. A ribosome produces a protein by chaining together amino acids. The chain then folds into the protein's functional shape. All proteins are produced by ribosomes according to this fundamental process. This is where we look for new drugs.

Our PSM technology uses *fluorescent tags* to label the protein assembly line. With these tags, *the ribosome broadcasts light pulses as it assembles the protein*. The light pulses form a fingerprint, a unique identifier for each type of protein.

Our platform analyzes the light signals to tell where, when and which proteins are being synthesized in the cell. We use high throughput screening methods to identify novel molecules that inhibit the synthesis of the target protein associated with the disease. Such molecules appear as "turning-off the lights" in the cells.

Patents

Our platform is protected by 6 patent families, of which 4 have already been granted and 2 are pending. We continue to build a strong IP portfolio around PSM technology.

Proof of concept

8 peer reviewed publications in leading scientific journals and further proven by dozens of collaborating research labs around the world in a wide variety of applications including neurobiology, cancer, novel antibiotics, viral infections and fibrosis.

Anima's drug discovery programs – current therapeutic areas

Our drug discovery programs currently focus on diseases that are closely related to aberrations in protein production: neuro-developmental (Autism), Fibrosis and Viral infections.

Business model

We discover novel protein synthesis inhibitors in high potential therapeutic areas and license them to pharma companies at the pre-clinical stage, deriving up front payments and future royalties. The big investments in clinical trials and taking drugs to the market are done by the pharma partners. Over time, with growing credibility and initial revenues we intend to develop further our most promising lead and maximize the value in the licensing deals (this business model is similar to what ISIS Pharmaceuticals has done with their siRNA platform – a strong model for wide scope platforms)

Anima Biotech Ltd.

www.animabiotech.com

Yochi Slonim, President and CEO

Tel: +972.544.892.175

Yochi.Slonim@animabiotech.com

Management

Yochi Slonim, president & CEO:

Mr. Slonim is a serial entrepreneur with over 25 years of experience of building startups into major companies. An active investor in Anima from seed stage, he served as the company's chairman and then as president and CEO. Before that, Mr. Slonim founded FFWD.me, a startup accelerator; founder and CEO of Identify until the company's acquisition for \$150m; Executive Vice President of Tecnomatix, a public NASDAQ company that was acquired for \$220m, and co-founder, CTO and VP R&D of Mercury Interactive that was acquired for \$4.5B.

Zeev Smilansky, Founder, CSO: Dr. Smilansky, the inventor of PSM technology and a mathematician by training, serves as the company's Chief Science Officer. He has over 25 years' experience in leading R&D groups and 15 years in biotechnology. In Compugen, as VP Proteomics, Smilansky led the company's bio-tools group; in Procognia he led the development of an automated lectin-based protein glycosylation analysis system.

Iris Alroy, VP R&D: Iris Alroy, Ph.D. has vast experience in drug discovery and preclinical development. Iris managed the R&D at Proteologics, was SVP Drug Discovery at Pharmos Ltd., and a partner at R&D Integrative Solutions, a pre-clinical and clinical consultancy. Iris led the discovery of small molecule CB2 agonists from hit optimization toward Phase II studies in pain.

Company status

Private company

Raised \$10m in grants (NIST, NIH)

Raised \$5.2m from investors


Technology proven with dozens of labs

8 publications with more under work


4 patents approved, 2 pending



What is it that makes life happen? If we could understand the process of life inside living cells, then our ability to understand and treat disease could be transformed and development of new drugs would be revolutionized. Inside the cells of our body billions of proteins are being produced. Diseases like Cancer, Fibrosis, Viral infections and many others are caused when the production of certain proteins gets out of control. Drugs try to bind to target proteins to fix the problems. However, proteins are so complex and modifying their behavior so difficult that for many severe diseases, no one has succeeded in finding such drugs. With Anima's technology we can see, for the first time, the protein synthesis process inside living cells. With our drug discovery platform, we can find new drugs that act as protein synthesis blockers; small molecule drugs bring the production of these proteins back under control.




Proteins have an amazing variety of shape, structure and function but they are all made in the same way.



In the cells, hundreds of thousands of Ribosomes produce proteins according to the cell's ever-changing needs.

A ribosome produces a protein by chaining together amino acids. The chain then folds into the protein's functional shape.

Anima's PSM technology uses fluorescent tags to label the protein assembly line.



With these tags, the ribosome broadcasts light pulses as it assembles the protein.

The light pulses form a "fingerprint" - a unique identifier that we use to monitor the production of the protein.

This fingerprint is the key to identifying, in real time, which protein is being produced.

With our technology, we now have new glasses that see into this fundamental life process of protein synthesis. We can distinguish between healthy and diseased cells, find new drugs, and understand how they function. We have discovered a rich source for new drugs and new hope that can we can win the battle against some of the world's most severe diseases.